Therefore, it seems reasonable that efforts be directed towards improving TTR in hemodialysis patients to bring them into line with those achieved in other populations with atrial fibrillation, in whom warfarin treatment has been decidedly beneficial. The gene discussed is TTR; the disease is atrial fibrillation.